Literature DB >> 17326614

Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.

Graham J Atwell1, Shangjin Yang, Frederik B Pruijn, Susan M Pullen, Alison Hogg, Adam V Patterson, William R Wilson, William A Denny.   

Abstract

A series of 2,4-dinitrobenzamide mustards were prepared from 5-chloro-2,4-dinitrobenzoic acid or the corresponding 5-dimesylate mustard as potential prodrugs for gene-directed enzyme prodrug therapy (GDEPT) with the E. coli nfsB nitroreductase (NTR). The compounds, including 32 new examples, were evaluated in four pairs of NTR+ve/-ve cell lines for selective cytotoxicity (IC50 and IC50 ratios), in multicellular layer (MCL) cultures for bystander effects, and for in vivo activity against tumors grown from stably NTR transfected EMT6 and WiDr cells in nude mice. Multivariate regression analysis of the IC50 results was undertaken using a partial least-squares projection to latent structures model. In NTR-ve lines, cytotoxicity correlated positively with logP, negatively with hydrogen bond acceptors (HA) and donors (HD) in the amide side chain, and positively with the reactivity of the less-reactive leaving group of the mustard function, likely reflecting toxicity due to DNA monoadducts. Potency and selectivity for NTR+ve lines was increased by logP and HD, decreased by HA, and was positively correlated with the leaving group efficiency of the more-reactive group, likely reflecting DNA crosslinking. NTR selectivity was greatest for asymmetric chloro/mesylate and bromo/mesylate mustards. Bystander effects in the MCL assay also correlated positively with logP and negatively with leaving group reactivity, presumably reflecting the transcellular diffusion/reaction properties of the activated metabolites. A total of 18 of 22 mustards showed equal or greater bystander efficiencies in MCLs than the aziridinylbenzamide CB 1954, which is currently in clinical trial for NTR-GDEPT. The dibromo and bromomesylate mustards were surprisingly well tolerated in mice. High MTD/IC50 (NTR+ve) ratios translated into curative activity of several compounds against NTR+ve tumors. A bromomesylate mustard showed superior activity against WiDr tumors grown from 1:9 mixtures of NTR+ve and NTR-ve cells, indicating a strong bystander effect in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17326614     DOI: 10.1021/jm061062o

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411NTR leading to therapeutic benefit.

Authors:  Dean C Singleton; Alexandra M Mowday; Chris P Guise; Sophie P Syddall; Sally Y Bai; Dan Li; Amir Ashoorzadeh; Jeff B Smaill; William R Wilson; Adam V Patterson
Journal:  Cancer Gene Ther       Date:  2021-11-26       Impact factor: 5.854

Review 2.  Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.

Authors:  Annika Foehrenbacher; Timothy W Secomb; William R Wilson; Kevin O Hicks
Journal:  Front Oncol       Date:  2013-12-27       Impact factor: 6.244

3.  Asymmetric and Reduced Xanthene Fluorophores: Synthesis, Photochemical Properties, and Application to Activatable Fluorescent Probes for Detection of Nitroreductase.

Authors:  Kunal N More; Tae-Hwan Lim; Julie Kang; Hwayoung Yun; Sung-Tae Yee; Dong-Jo Chang
Journal:  Molecules       Date:  2019-09-03       Impact factor: 4.411

4.  Interrogation of the Structure-Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications.

Authors:  Amir Ashoorzadeh; Alexandra M Mowday; Christopher P Guise; Shevan Silva; Matthew R Bull; Maria R Abbattista; Janine N Copp; Elsie M Williams; David F Ackerley; Adam V Patterson; Jeff B Smaill
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-01

5.  Calcium Enabled Remote Loading of a Weak Acid Into pH-sensitive Liposomes and Augmented Cytosolic Delivery to Cancer Cells via the Proton Sponge Effect.

Authors:  Mimi M Yang; Sasi Bhushan Yarragudi; Stephen M F Jamieson; Mingtan Tang; William R Wilson; Zimei Wu
Journal:  Pharm Res       Date:  2022-02-28       Impact factor: 4.580

6.  E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954.

Authors:  S O Vass; D Jarrom; W R Wilson; E I Hyde; P F Searle
Journal:  Br J Cancer       Date:  2009-05-19       Impact factor: 7.640

7.  Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures.

Authors:  Cho R Hong; Gib Bogle; Jingli Wang; Kashyap Patel; Frederik B Pruijn; William R Wilson; Kevin O Hicks
Journal:  Front Pharmacol       Date:  2018-09-18       Impact factor: 5.810

8.  Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3.

Authors:  Maria R Abbattista; Amir Ashoorzadeh; Christopher P Guise; Alexandra M Mowday; Rituparna Mittra; Shevan Silva; Kevin O Hicks; Matthew R Bull; Victoria Jackson-Patel; Xiaojing Lin; Gareth A Prosser; Neil K Lambie; Gabi U Dachs; David F Ackerley; Jeff B Smaill; Adam V Patterson
Journal:  Pharmaceuticals (Basel)       Date:  2021-11-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.